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Type I IL-1 Receptor Mediates IL-1 and Intracellular
IL-1 Receptor Antagonist Effects in Skin Inflammation
Gaby Palmer1,2, Dominique Talabot-Ayer1,2, Gu¨rkan Kaya3 and Cem Gabay1,2
The IL-1 system plays a key role in skin physiology and pathology. In this study, we used mutant mice lacking the
type I IL-1 receptor (IL-1RI), lacking IL-1 receptor antagonist (IL-1Ra), or overexpressing the human intracellular
(ic) IL-1Ra1 isoform, as well as combinations thereof, to dissect the role of the IL-1 system in phorbol 13-
myristate 12-acetate (PMA)-induced skin inflammation. In wild-type (WT) mice, PMA application induced
epidermal thickening and dermal inflammation. Skin IL-1a production and circulating levels of the acute-phase
protein serum amyloid A (SAA) were elevated. In mice lacking IL-1RI or overexpressing icIL-1Ra1, PMA induced
similar epidermal thickening as in WT mice, but dermal inflammation was partially prevented. Skin IL-1a mRNA
expression was similar in PMA-treated IL-1RI/ and WT mice, whereas the increase in serum SAA was
suppressed in IL-1RI/ mice. Interestingly, PMA-induced IL-1a mRNA expression was further enhanced by icIL-
1Ra1 overexpression in an IL-1RI-dependent manner. Finally, IL-1Ra/ mice spontaneously displayed skin
lesions characterized by high IL-1b, but not IL-1a, expression. In conclusion, PMA-induced epidermal thickening
and skin IL-1a expression were independent of IL-1 signaling, in contrast to dermal inflammation and systemic
inflammatory response.
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INTRODUCTION
IL1 activity is mediated by two cytokines, IL-1a and IL-1b,
which are produced by two different genes and share 26%
amino-acid homology (see Dinarello (1996) for a review).
IL-1b is primarily produced by monocytes and macrophages
and is secreted after cleavage of its proform by IL-1b-
convertase enzyme (also termed ‘caspase-1’). IL-1a is synthe-
sized as a 31-kDa precursor peptide, which is specifically
cleaved by calpain-like proteases to generate C-terminal
mature 17 kDa IL-1a and a N-terminal 16 kDa propeptide.
Although pre-IL-1b is biologically inactive, both precursor
and mature forms of IL-1a are able to bind to IL-1 receptors
and activate intracellular signaling. IL-1 treatment of cells
induces the formation of a high-affinity complex containing
the type I IL-1 receptor (IL-1RI) and IL-1 receptor accessory
protein (IL-1RAcP). The intracellular domains of IL-1RI and
IL-1 receptor accessory protein then recruit the adapter
protein MyD88 and IL-1 receptor-associated kinases, which
are the proximal mediators of IL-1 signaling (O’Neill, 2002).
IL-1 receptor antagonist (IL-1Ra) is a natural inhibitor of
IL-1 activity. IL-1Ra binds to cell surface IL-1 receptors, but
does not recruit IL-1RAcP and thus does not induce any intra-
cellular response (see Arend et al. (1998) for a review). IL-1Ra
prevents the interaction between IL-1 and its receptors, and
thus competitively inhibits its biological effects. IL-1Ra is
produced as four different isoforms, one secreted (sIL-1Ra)
and three intracellular (icIL-1Ra1, 2, 3), derived from the
same gene (Arend et al., 1998). The biological function of
intracellular variants of IL-1Ra remains unclear. Intracellular
IL-1Ra isoforms are able to prevent the binding of IL-1 to its
cell-surface receptors. However, owing to their intracellular
localization, icIL-1Ra isoforms cannot interact with cell
surface IL-1 receptors unless released by dying cells or upon
appropriate cellular activation (Lee et al., 1997; Levine et al.,
1997; Wilson et al., 2004). In addition, several in vitro studies
using different types of epithelial cells and dermal fibro-
blasts have suggested that icIL-1Ra1 carries out specific anti-
inflammatory functions inside cells, independently of IL-1RI
binding (Watson et al., 1995; Garat and Arend, 2003; Banda
et al., 2005; Kanangat et al., 2006). However, these obser-
vations have not been confirmed in other studies (Muzio
et al., 1999; Evans et al., 2006). In addition, no IL-1RI-inde-
pendent effect of icIL-1Ra isoforms has been documented
in vivo so far. In contrast, deletion of the IL-1Ra and IL-1RI
genes proved to be epistatic for various phenotypes analyzed
in knockout mice, indicating that all examined functions of
IL-1Ra depended on the presence of a functional receptor
(Irikura et al., 2002).
ORIGINAL ARTICLE
1938 Journal of Investigative Dermatology (2007), Volume 127 & 2007 The Society for Investigative Dermatology
Received 17 November 2006; revised 10 January 2007; accepted 26 January
2007; published online 3 May 2007
1Division of Rheumatology, University Hospital, Geneva, Switzerland;
2Department of Pathology and Immunology, University of Geneva School of
Medicine, Geneva, Switzerland and 3Department of Dermatology, University
Hospital, Geneva, Switzerland
Correspondence: Dr Cem Gabay, Division of Rheumatology, University
Hospital, 26 av. Beau-Se´jour, Geneva 14 1211, Switzerland.
E-mail: Cem.Gabay@hcuge.ch
Abbreviations: ANOVA, analysis of variance; icIL-1Ra1, intracellular IL-1
receptor antagonist type I; IL-1RI, type I IL-1 receptor; IL-1Ra, IL-1Ra receptor
antagonist; IL-1RAcP, IL-1 receptor accessory protein; MEF, mouse embryonic
fibroblast; MIF, macrophage migration inhibitory factor; PMA, phorbol
13-myristate 12-acetate; SAA, serum amyloid A; tg, transgenic; WT, wild type
Keratinocytes constitutively produce high amounts of IL-
1a and the epidermis contains important quantities of
biologically active preformed IL-1a (Murphy et al., 2000).
In addition, human, but not mouse, keratinocytes also
produce limited amounts of IL-1b in inflammatory conditions
(Ansel et al., 1988; Zepter et al., 1997). Furthermore, kerati-
nocytes produce high amounts of icIL-1Ra1 isoform (Bigler
et al., 1992), as well as IL-1RI and the type II, non-signal
transducing IL-1 receptor. All elements of IL-1 system are thus
represented in the epidermis and IL-1 is believed to be
centrally involved in cutaneous physiology and pathology
(Murphy et al., 2000). Deregulation of IL-1 system has been
suggested to play a role in inflammatory skin diseases.
Indeed, overexpression of IL-1a in the epidermis causes
spontaneous skin disease characterized by hair loss, scaling,
and focal inflammatory skin lesions (Groves et al., 1995).
Moreover BALB/c designates a mouse genetic background
IL-1Ra / mice develop inflammation of the skin of the ear
pinna with many features resembling psoriasis (Shepherd
et al., 2004).
The application of phorbol 13-myristate 12-acetate (PMA)
to mouse skin results in an acute inflammatory response,
including epidermal hyperplasia, abnormal keratinocyte
differentiation, alteration of keratin expression, increased
IL-1a production, and leukocyte infiltration (Reynolds et al.,
1998). Experiments with blocking antibodies have implicated
IL-1a as a mediator of inflammatory cell infiltration and
epidermal hyperplasia induced by PMA treatment (Lee et al.,
1994). In this study, we wanted to further dissect the role
of the IL-1 system in response to PMA skin painting using
mutant mice lacking IL-1RI or IL-1Ra, or overexpressing the
human icIL-1Ra1 isoform. Furthermore, as contradictory
findings have been reported concerning the existence of
intracellular effects of icIL-1Ra1 in different cell types in vitro,
we used icIL-1Ra1 transgenic (tg) mice lacking both endo-
genous IL-1Ra isoforms and the IL-1RI to specifically
investigate potential IL-1RI-independent effects of icIL-1Ra1
in a model of skin inflammation in vivo. Finally, we also
examined the effects of icIL-1Ra1 overexpression on cytokine
production in different cell types in vitro.
RESULTS
We first assessed the cutaneous inflammatory response to
three repeated applications of PMA on the back of wild-type
(WT) DBA/1 mice. Two days after the last application of
PMA, skin histology showed a marked epidermal thickening
and significantly increased infiltration of inflammatory cells,
mainly polymorphonuclear cells, into the dermis (Figure 1a
and b). We examined the local expression of various cyto-
kines in acetone or PMA-treated skin of WT mice by RNase
protection assay. Among the cytokines tested, we observed
strong expression of IL-1a, IL-1Ra, IL-18, and macrophage
migration inhibitory factor (MIF) in PMA-treated WT skin and
lower levels of IL-1b and IL-6. Although mRNA expression
tended to be higher in PMA-treated skin for all cytokines,
only IL-1a and IL-1Ra mRNA levels were significantly
increased (Figure 1c). MIF levels were high in the skin of
acetone-treated WT mice and not significantly increased by
PMA treatment (WT acetone, n¼3: 341731 arbitrary units
(AU); WT PMA, n¼8: 431744, AU; P40.05). We also
evaluated the systemic response to PMA treatment by
measuring serum amyloid A (SAA) and IL-6 levels as markers
of the acute-phase response. PMA application significantly
increased SAA levels (Figure 1d), but circulating IL-6 levels
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Figure 1. PMA-induced skin inflammation in WT mice. (a) Representative
histological sections of acetone (upper panel, original magnification  20)
and PMA-treated (lower panel, original magnification  20, scale
bar¼ 500 mm) skin of WT mice are shown. PMA treatment resulted in marked
epidermal thickening and increased infiltration of inflammatory cells into the
dermis. (b) Results of histological scoring for epidermal thickness (left panel)
and dermal inflammatory cell infiltration (right panel) are shown for acetone
(white columns; n¼ 5) and PMA-treated (black columns; n¼8) WT mice.
Results shown represent the mean7SEM for each group of mice. *Po0.05
versus acetone-treated WT mice, as assessed by t-test. PMA painting induced
a significant increase in both epidermal thickness and inflammatory cell
infiltration. (c) Cytokine mRNA expression in the skin was analyzed by RNase
protection assay and quantified by phosphorimaging for acetone (white
columns; n¼ 3) and PMA-treated (black columns; n¼ 8) WT mice. Results are
expressed as the ratio of cytokine over L32 mRNA expression. Results shown
represent the mean7SEM for each group of mice. *Po0.05 versus acetone-
treated WT mice, as assessed by t-test. AU, arbitrary units. IL-1a and IL-1Ra
mRNA expression was significantly increased in PMA-treated WT mice.
(d) Circulating SAA levels were assessed by ELISA in the serum of acetone
(white columns; n¼ 5) or PMA-treated (black columns; n¼8) WT mice.
Results shown represent the mean7SEM for each group of mice. *Po0.05
versus acetone-treated WT mice, as assessed by t-test. Serum SAA was
significantly elevated in PMA-treated WT mice.
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were below the limit of detection of the ELISA in both PMA
and acetone-treated WT mice.
PMA-induced skin inflammation in absence of IL-1 activity
We bred various mutant mouse lines either lacking IL-1RI or
overexpressing the human icIL-1Ra1 isoform in presence or
absence of endogenous IL-1Ra. These mutant mice were used
to investigate the response to PMA skin painting in absence of
IL-1 activity. In addition, we used icIL-1Ra1 tg mice lacking
both endogenous IL-1Ra isoforms and the IL-RI to investigate
potential IL-1RI-independent effects of icIL-1Ra1. Histologi-
cal analysis of PMA-treated skin indicated that epidermal
thickness was similar in all groups of mice (Figure 2a),
whereas inflammatory cell infiltration into the dermis was
partially prevented in mice overexpressing icIL-1Ra1 and/or
lacking IL-1RI, in presence or in absence of endogenous
IL-1Ra (Figure 2b). Dermal cell infiltration (mean7SEM)
was: 239711 in WT (n¼8), 17875 in IL-1RI / (n¼ 5,
P¼0.001 versus WT), 201712 in icIL-1Ra1 tg (n¼4,
P¼0.0473 versus WT), 15474 in IL-1Ra / icIL-1Ra1
tg (n¼ 5, Po0.0001 versus WT), 15074 in IL-1Ra /
IL-1RI/ (n¼5, Po0.0001 versus WT) and 16072 in
IL-1Ra/ IL-1RI/ icIL-1Ra1 tg mice (n¼8, Po0.0001
versus WT). The effect of PMA on epidermal thickening is
thus most likely direct, rather than IL-1 mediated, whereas
inflammatory cell infiltration is partly IL-1 dependent.
Skin IL-1a mRNA expression was similarly elevated after
PMA treatment in IL-1RI/ mice, in presence or absence of
endogenous IL-1Ra, and in WT mice (Figure 2c). This
increase thus likely reflects a direct effect of PMA on kerati-
nocytes and is not IL-1RI-signaling dependent. Interestingly
IL-1a mRNA expression was significantly higher in PMA-
treated skin of mice overexpressing icIL-1Ra1, in presence
and in absence of endogenous IL-1Ra, as compared with the
skin of PMA-treated WT mice. This effect of icIL-1Ra1
overexpression was dependent on the presence of IL-1RI, as
it was not observed in IL-1Ra/ IL-1RI/ icIL-1Ra1 tg
mice (Figure 2c). Expression of endogenous mouse (m) IL-1Ra
(mIL-1Ra) mRNA was similar in PMA-treated skin of WT,
icIL-1Ra1 tg, and IL-1RI/ mice, whereas single and
combined IL-1Ra/ mutants obviously lacked mIL-1Ra
mRNA (Figure 4c and data not shown). The PMA-induced
increase in serum SAA levels was abolished in mice
overexpressing icIL-1Ra1, deficient for IL-RI, or both, even
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Figure 2. PMA-induced skin inflammation in absence of IL-1 activity. Results of histological scoring for (a) epidermal thickness and (b) dermal inflammatory
cell infiltration are shown for PMA-treated WT (n¼ 8), IL-1RI/ (n¼ 5), icIL-1Ra1 tg (n¼ 4), IL-1Ra/ icIL-1Ra1 tg (n¼ 5), IL-1Ra/ IL-1RI/ (n¼ 5) and
IL-1Ra/ IL-1RI/ icIL-1Ra1 tg mice (n¼8). Results shown represent the mean7SEM for each group of mice. *Po0.05 versus WT mice, as assessed by
analysis of variance (ANOVA). Epidermal thickness was similar in all groups of mice, whereas inflammatory cell infiltration was significantly decreased in mice lacking
IL-1RI and/or overexpressing icIL-1Ra1, in presence or in absence of endogenous IL-1Ra. (c) IL-1a mRNA expression was analyzed by RNase protection assay and
quantified by phosphorimaging in PMA-treated WT (n¼8), IL-1RI/ (n¼ 5), icIL-1Ra1 tg (n¼ 4), IL-1Ra/ icIL-1Ra1 tg (n¼ 5), IL-1Ra/ IL-1RI/ (n¼ 5),
and IL-1Ra/ IL-1RI/ icIL-1Ra1 tg mice (n¼ 8). Results are expressed as the ratio of IL-1a over L32 mRNA expression. Results shown represent the
mean7SEM for each group of mice. *Po0.05 versus WT mice, as assessed by ANOVA. AU, arbitrary units. IL-1amRNA levels were significantly elevated in icIL-1Ra1
tg and in IL-1Ra/ icIL-1Ra1 tg, as compared with WT mice. (d) Circulating SAA levels were assessed by ELISA in the serum of PMA-treated WT (n¼8), IL-1RI/
(n¼ 5), icIL-1Ra1 tg (n¼4), IL-1Ra/ icIL-1Ra1 tg (n¼5), IL-1Ra/ IL-1RI/ (n¼ 5) and IL-1Ra/ IL-1RI/ icIL-1Ra1 tg mice (n¼8). Results shown
represent the mean7SEM for each group of mice. *Po0.05 versus WT mice, as assessed by ANOVA. SAA levels were significantly lower in PMA-treated mice lacking
IL-1RI and/or overexpressing icIL-1Ra1, in presence or in absence of endogenous IL-1Ra.
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in the absence of endogenous IL-1Ra, indicating that the
systemic inflammatory response to PMA treatment of the skin
is critically dependent on IL-1 signaling (Figure 2d).
Skin phenotype of IL-1Ra/ mutant mice
We next examined the phenotype of IL-1Ra/ mice, where
IL-1 activity is not counterbalanced by IL-1Ra. The IL-1Ra/
mice used in this study lack all IL-1Ra isoforms. These mice
were backcrossed for six generations or more into DBA/1
background. They were bred and housed in our conventional
animal facility and displayed a general phenotype very
similar to that previously reported for IL-1Ra/ mice in the
C57BL/6 background (Irikura et al., 2002). In particular, we
observed decreased fertility, a general appearance suggesting
illness, which included runting, piloerection, and mild
weight loss, as well as, in some cases, moderate to severe
respiratory distress. Although young adult IL-1Ra/ mice
were generally asymptomatic, this illness phenotype increas-
ingly appeared with aging, and from 4 to 6 months of age,
all mice displayed at least some of these symptoms. Crossing
IL-1Ra/ mice with icIL-1Ra1 tg and/or IL-1RI/ mice
completely reverted this general phenotype, confirming the
epistasis between IL-1Ra and IL-1RI, which had been previously
reported (Irikura et al., 2002). As in this previous report, we
failed to identify a specific defect to explain the ill health
observed in IL-1Ra/ mice, which is likely to be the con-
sequence of a chronic inflammatory state, caused by inadequate
perpetuation and amplification of various inflammatory
processes occurring in these mice throughout their lives.
IL-1Ra/ mice displayed a macroscopic skin phenotype
similar to that previously described in mice overexpressing
IL-1a in the skin (Groves et al., 1995). They had sparse hair,
particularly in the neck region and at the base of the tail, and
some IL-1Ra/ mice exhibited scaling and focal inflamma-
tory skin lesions, mostly situated on the back. These lesions
appeared with aging and were generally more pronounced
in old (44–6 months) mice. As for their general ill-health
phenotype, crossing of IL-1Ra/ mice with icIL-1Ra1 tg
and/or IL-1RI/ mice completely abolished the apparition
of the skin phenotype. Although some control IL-1Ra/
mice displayed normal skin histology (Figure 3a, upper left
panel), marked spontaneous epidermal thickening, accom-
panied by increased dermal inflammatory cell infiltration,
could be observed in skin sections of about 40% of the
IL-1Ra/ mice (Figure 3a, upper right panel and Figure 3b).
However PMA-treated IL-1Ra/ mice displayed epidermal
thickening and inflammatory cell infiltration, indistinguish-
able from that observed in PMA-treated WT mice (Figure 3a,
lower panel and Figure 3b).
IL-1a mRNA expression was similar in acetone-treated
skin of WT and IL-1Ra/ mice, and comparably increased
upon PMA treatment for both genotypes (Figure 4a). Parallel
changes were also observed for IL-1a protein expression in
the skin of WT and IL-1Ra/ mice (Table 1). By immuno-
histochemistry, high IL-1a expression was detected in parti-
cular in the epidermis of PMA-treated WT and IL-1Ra/
mice (Figure 4b). Interestingly, we detected increased IL-1b
mRNA expression in the skin of IL-1Ra/ knockout mice
(Figure 4c). IL-1b mRNA expression was variable and
reached remarkably high levels in some mice. High IL-1b
mRNA expression correlated with the presence of macro-
scopic skin lesions (Figure 4c, right panel). In contrast to
IL-1a, IL-1b mRNA expression was not significantly affected
by PMA treatment in either WT or IL-1Ra/ mice (Figure 4a
and c). IL-1b protein levels paralleled IL-1bmRNA expression
in the skin of WT and IL-1Ra/ mice (Table 1). Again, we
observed a high inter-individual variability in IL-1b protein
expression levels, which was highest in IL-1Ra/ mice
displaying important macroscopic skin lesions.
Consistently with their general ill health and skin pheno-
type, IL-1Ra/ mice had spontaneously elevated serum
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Figure 3. Skin phenotype in acetone and PMA-treated IL-1Ra/ mice.
(a) Representative histological sections of acetone (upper panels, original
magnification  20, bar¼ 500 mm) and PMA-treated (lower panel, original
magnification  20) skin of IL-1Ra/ mice are shown. Although some
control IL-1Ra/ mice displayed normal skin histology (upper left panel),
marked spontaneous epidermal thickening, accompanied by inflammatory
cell infiltration into the dermis, could be observed in about 40% of the
IL-1Ra/ mice (upper right panel). PMA-treated IL-1Ra/ mice displayed
epidermal thickening and dermal inflammatory cell infiltration similar to
that observed in PMA-treated WT mice. (b) Results of histological scoring
for epidermal thickness (left panel) or inflammatory cell infiltration (right
panel) are shown for acetone (white columns; n¼ 5 per genotype) or
PMA-treated (black columns; n¼ 8 per genotype) WT and IL-1Ra/ mice.
Results shown represent the mean7SEM for each group of mice. *Po0.05
versus acetone-treated WT mice, as assessed by ANOVA. IL-1Ra/ mice
spontaneously displayed an increased epidermal thickness and a trend for
higher inflammatory cell infiltration into the dermis. PMA painting resulted
in similar epidermal thickening and dermal inflammatory cell infiltration
in WT and IL-1Ra/ mice.
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SAA levels (Figure 4d). Although PMA application signifi-
cantly increased SAA levels in WT mice, values in IL-1Ra/
mice were not further enhanced. Serum IL-6 levels remained
below the detection limit of the test in all the different WT
and mutant mice, except in some acetone or PMA-treated
IL-1Ra/ mice, where serum IL-6 ranged from 18 to 375 pg/
ml. Highest IL-6 levels were observed in old IL-1Ra/ mice
displaying a marked general illness phenotype and spontaneous
macroscopic skin lesions, independently of PMA treatment.
DISCUSSION
We characterized the effects of repeated applications of PMA
onto the skin of WT and mutant DBA/1 mice. In WT mice, we
observed epidermal hyperplasia, inflammatory cell infiltra-
tion into the dermis, and increased expression of IL-1a and IL-
1Ra in the skin, as previously reported after a single
application of PMA in different strains of mice (Oberyszyn
et al., 1993; Lee et al., 1994; Reynolds et al., 1998; La et al.,
1999). We also observed a trend toward increased expression
of other cytokines such as IL-18, IL-6, and MIF. IL-1b
expression was rather low. Finally, repeated PMA treatment
of the skin also induced a systemic inflammatory response, as
indicated by increased circulating levels of SAA.
We then examined the response to PMA skin painting
in absence of IL-1 signaling. IL-1RI/ mice have been
characterized previously for their lack of responsiveness to
Table 1. IL-1a and IL-1b protein levels in skin lysates
Genotype Treatment
IL-1a (ng/mg
protein)1
IL-1b (pg/mg
protein)1
WT Acetone 5.170.4 1673
PMA 10.972.62 2873
IL-Ra/ Acetone 1.770.7 5117295
PMA 7.171.052 3107242
1Cytokine levels are shown for acetone (n=3) or PMA-treated (n=3) WT
mice, and acetone (n=4) or PMA-treated (n=4) IL-1Ra/ mice. Results
shown represent the mean7SEM for each group of mice.
2Po0.05 versus acetone-treated mice of same genotype, as assessed
by t-test.
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Figure 4. Skin IL-1a and IL-1b mRNA expression and systemic inflammatory response in IL-1Ra/ mice. (a) IL-1a mRNA levels were quantified by
RNase protection assay for acetone (white columns; WT, n¼ 3; IL-1Ra/, n¼5) or PMA-treated (black columns; n¼8 per genotype) WT and IL-1Ra/ mice.
Results shown represent the mean7SEM for each group of mice. *Po0.05 versus acetone-treated WT mice, as assessed by ANOVA. AU, arbitrary units. PMA
painting resulted in similar changes in IL-1amRNA expression in WT and IL-1Ra/ mice. (b) IL-1a protein expression was examined by immunohistochemistry
in PMA-treated skin of WT (upper left panel, original magnification  20) and IL-1Ra/ mice (lower left panel, original magnification 20). Incubations
without the first antibody are shown as negative controls (right panels, original magnification  20, bar¼ 500mm). High IL-1a expression was observed in
particular in the epidermis. (c) Left panel: a representative RNase protection assay is shown for skin RNA isolated from a PMA-treated WT mouse (lane 1) and
an acetone-treated IL-1Ra / mouse (lane 2). The identity of the detected bands is indicated on the left. Middle panel: IL-1b mRNA levels were quantified
by RNase protection assay for acetone (white columns; WT, n¼ 3; IL-1Ra/, n¼ 5) or PMA-treated (black columns; n¼8 per genotype) WT and IL-1Ra/
mice. Results shown represent the mean7SEM for each group of mice. AU, arbitrary units. Right panel: IL-1b mRNA levels correlated with the severity of
macroscopic skin lesions observed on IL-1Ra/ mice (n¼ 12, P¼ 0.0015 as assessed by Spearman’s correlation). The graph shows a linear regression of
IL-1b mRNA expression levels as a function of macroscopic skin lesion scores (r2¼0.664). (d) Circulating SAA levels were assessed by ELISA in the serum
of acetone (white columns; n¼ 5 per genotype) or PMA-treated (black columns; n¼ 8 per genotype) WT and IL-1Ra/ mice. Results shown represent the
mean7SEM for each group of mice. *Po0.05 versus acetone-treated WT mice, as assessed by ANOVA. SAA was significantly increased in acetone-treated
IL-1Ra/ as compared with WT mice. SAA levels were similar in PMA-treated WT and IL-1Ra/ mice.
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IL-1 (Glaccum et al., 1997), which we further confirmed
using in vitro cultures of mouse embryonic fibroblast isolated
from these mice. Similarly, icIL-1Ra1 tg mice express the
human icIL-1Ra1 from a strong ubiquitous promoter, which
results in overexpression in all tissues and cell types
examined, including keratinocytes and dermal fibroblasts,
as well as in high circulating levels of hIL-1Ra1 in the serum
(Gabay et al., 2001; Palmer et al., 2003). These mice are
completely resistant to collagen-induced arthritis, an experi-
mental model of immune-mediated arthritis which is strongly
IL-1 dependent (Palmer et al., 2003). Using mutant mice
lacking IL-1RI or overexpressing icIL-1Ra1, we observed that
epidermal thickening and IL-1a expression induced by repea-
ted PMA treatment of the skin are independent of IL-1
signaling, in contrast to dermal inflammation and systemic
inflammatory response, which are respectively partially and
completely inhibited in absence of IL-1 activity. The effect
of PMA on IL-1a expression in the epidermis likely reflects
a direct effect of this compound on keratinocytes (Lee et al.,
1993), which we also observed in keratinocyte cultures
in vitro. In addition to IL-1a, PMA may also directly induce
the production of other cytokines and chemokines, including
tumor necrosis factor-a, monocyte chemoattractant protein-1,
and macrophage inflammatory protein-2 (Jamieson et al.,
2005; Murakawa et al., 2006), which are likely to contribute
to inflammatory cell infiltration into the dermis.
Our findings are somewhat different from previously
reported observations, which indicated that local or systemic
treatment of mice with anti-IL-1a antibodies, as well as
overexpression of the inhibitory type II IL-1 receptor in
keratinocytes, blocked both PMA-induced epidermal thicken-
ing and skin inflammation (Oberyszyn et al., 1993; Lee et al.,
1994; Rauschmayr et al., 1997). The studies using anti-IL-1a
antibodies examined only the acute inflammation induced by a
single application of PMA, and this difference in the
experimental protocol might account for differences observed.
We used, indeed, a more stringent model of multiple PMA
applications (Jamieson et al., 2005) and it has been observed
previously that some pharmacological agents, which are active
in the acute PMA model, are not efficient in multiple appli-
cation models (Stanley et al., 1991). In a preliminary experi-
ment, we compared the effect of a single PMA application on
WT and icIL-1Ra1 tg mice. We observed marked epidermal
thickening in WT mice 48 hours after a single application of
PMA. Epidermal thickening was also observed in icIL-1Ra1 tg
mice, although it appeared reduced as compared with WT
mice, suggesting that the effect of a single PMA application is
indeed partially prevented in icIL-1Ra 1 tg mice. However, this
observation is still different from the results reported by Lee
et al. (1994), who showed that epidermal thickening induced
by a single PMA application was totally inhibited by injection
of anti-IL-1a antibodies. It thus has to be stressed that the
difference in the experimental protocols used is only one
potential explanation for the discrepancies observed between
different studies. Indeed, overexpression of type II IL-1 receptor
was also reported to decrease epidermal thickening after
multiple PMA applications (Rauschmayr et al., 1997), suggest-
ing that additional factors, such as for instance the use of
different mouse strains and different genetic backgrounds,
might influence the results obtained.
IL-1a mRNA expression was significantly higher in PMA-
treated skin of icIL-1Ra1 overexpressing, as compared with
WT mice and this effect was dependent on the presence of
IL-1RI. Although the exact mechanism underlying this effect
is not clear, this observation is consistent with a recent study
describing mutual upregulation of IL-1a and IL-1Ra expres-
sion in mouse keratinocytes, in which IL-1a release was
found to be increased several folds in epidermal sheets
derived from IL-1Ra tg epidermis (Mee et al., 2005).
Altogether, the effects of icIL-1Ra1 overexpression, which
we observed in this model of PMA-induced skin inflamma-
tion, were either similar to those observed upon deletion
of IL-1RI or IL-1RI dependent. These effects are thus likely
mediated by binding of extracellular icIL-1Ra1, which circu-
lates at high levels in icIL-1Ra1 tg mice (Palmer et al., 2003),
to IL-1RI. In addition, as previously described in other models
(Irikura et al., 2002), the effects of IL-1Ra and IL-RI deletion
on both the general and the cutaneous phenotype were
epistatic, suggesting that all effects of IL-1Ra are mediated by
IL-1RI. We thus failed to observe any IL-1RI-independent
effects of icIL-1Ra1 in skin inflammation in vivo. However,
given the existence of previous reports describing intra-
cellular anti-inflammatory activity of icIL-1Ra 1 in human
keratinocyte cell lines and dermal fibroblasts (Banda et al.,
2005; Kanangat et al., 2006), we further investigated
potential effects of icIL-1Ra1 in vitro using cultures of various
cell types derived from our mutant mice, including keratino-
cytes, dermal fibroblasts, embryonic fibroblasts, and bone
marrow-derived macrophages (data not shown). We could
not observe any anti-inflammatory effect of icIL-1Ra1 over-
expression on cytokine production in the different cell types
examined. There are some differences in the experimental
systems and readouts used between our experiments and
previous studies in human cells and the results obtained are
thus not directly comparable. Nevertheless, our observations
argue against an anti-inflammatory effect of intracellular
IL-1Ra in mouse primary cell cultures.
DBA/1 IL-1Ra/ mice displayed a spontaneous skin
phenotype very similar to the one described for mice
overexpressing IL-1a in the epidermis (Groves et al., 1995).
In contrast, their ears appeared normal, and their skin lesions
differed from the psoriasis-like modifications described on the
ears of IL-1Ra/ mice bred into the BALB/c background.
These observations further emphasize the strong background
dependence of the different inflammatory diseases that have
been described in IL-1Ra/ mice (Horai et al., 2000;
Nicklin et al., 2000). Interestingly, although PMA treatment
preferentially increased IL-1a expression, the spontaneous
skin lesions of IL-1Ra/ mice correlated with high IL-1b
expression, suggesting that these two homologous cytokines
play distinct roles in different types of skin inflammation.
In conclusion, epidermal thickening and IL-1a expression
induced by repeated PMA treatment of the skin were
independent of IL-1 signaling, in contrast to dermal inflamma-
tion and systemic inflammatory response. We failed to detect
any IL-1RI-independent effects of icIL-1Ra1 in this model of
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skin inflammation. Finally, IL-1Ra/ mice displayed sponta-
neous skin lesions characterized by high IL-1b expression.
MATERIALS AND METHODS
Mice
WT DBA/1 mice were obtained from Janvier (Le Genest St Isle,
France). IL-1Ra/ mice were originally obtained from Dr E Hirsch
(Hirsch et al., 1996) and backcrossed for more than six generations
into the DBA/1 background. IL-1RI/ mice backcrossed for five
generations into the DBA/1 background were obtained from Amgen
Inc. (Thousand Oaks, CA) (Glaccum et al., 1997). Mice tg for the
human icIL-1Ra1 isoform were described previously (Gabay et al.,
2001) and backcrossed for more than 10 generations into the DBA/1
background. IL-1Ra/ and icIL-1Ra1 tg mice were crossed to
obtain IL-1Ra/ mice carrying the human icIL-1Ra1 transgene.
IL-1Ra/ icIL1-Ra1 tg mice were bred with IL-1RI/ mice to
create IL-1Ra and IL-1RI double knockout mice, as well as IL-1Ra and
IL-1RI double knockout mice carrying the human icIL-1Ra1 transgene.
IL-1Ra/, IL-1RI/, and double knockout mice were genotyped by
PCR using the following primer combinations: mIL-1Ra forward
50-aaccagctcattgctgggtactta-30 and mIL-1Ra reverse 50-gcccaagaaca
cactatgaaggtc-30 for IL-1Ra; mIL-1RI forward 50-gagttacccgaggtc
cagtgg-30, mIL-1RI reverse 50-ccgaagaagctcacgttgtcaag-30, and mIL-
1RI neo 50-gaatgggctgaccgcttcctcg-30 in a three primer PCR reactions
for IL-1RI. Expression of the human icIL-1Ra1 transgene was assessed
by ELISA in serum samples, as described by Palmer et al. (2003). All
single and double knockout mice used for the experiments described
in this study were homozygous, whereas icIL-1Ra1 tg mice were
hemizygous for the transgene. All mice were housed under
conventional conditions, and water and standard laboratory chow
were provided ad libitum. All animal experiments were approved by
the Animal Ethics Committee of the Geneva University School of
Medicine and by the Geneva Veterinarian Office.
PMA-induced skin inflammation
Male or female WT and mutant mice were used between 2 and 13
months of age. Their backs were shaved with electric clippers
3 days before experiments. PMA (Sigma, Buchs, Switzerland; 1 mg in
200ml acetone), or acetone (200 ml) for control mice, was applied
onto the dorsal surfaces of shaved mice. PMA, respectively acetone,
application was repeated 24 and 48 hours later (Jamieson et al.,
2005). Mice were killed 48 hours after the last application. At killing,
acetone or PMA-treated skin was dissected and cut into 2–3 small
pieces. One piece was fixed in 10% buffered formalin for
histological analysis and 1–2 pieces were immediately frozen in
liquid nitrogen and stored at 801C, until used for RNA or protein
lysate preparation.
Scoring of macroscopic skin lesion
Macroscopic skin lesions observed in IL-1Ra/ mice were scored on
a 4-point scale, in which 0¼ normal appearance, 1¼ localized hair
loss and scaling, 2¼ extensive hair loss and scaling with presence
of 1–2 inflammatory foci, 3¼ extensive hair loss, scaling, and presence
of scabs, and 4¼ extensive hair loss, scabs, and open wounds.
Histology
Skin samples were fixed in 10% phosphate-buffered formaldehyde,
embedded in paraffin, and processed for histological analysis.
Sections were cut at 5 mm, mounted onto slides, and stained with
hematoxylin and eosin according to the standard procedures.
Epidermal thickness measurements
Epidermal thickness of mice was measured with a Zeiss Axioskop 2
microscope using a graded ocular micrometer at  40 magnification
and multiplied by 10 to correct the scale. The evaluation was
performed by one of the authors (GK) in a masked fashion. Five
measurements were performed per mouse and the average value was
calculated.
Analysis of dermal cellularity
Dermal cells were counted with a Zeiss Axioskop 2 microscope at
 40 magnification. The evaluation was performed by one of the
authors (GK) in a masked fashion. Three counts were made per
mouse and the average value was calculated.
RNase protection assay
Small pieces of the skin were homogenized in Trizol reagent (Gibco,
Life Technologies AG, Basel, Switzerland) and total RNA was
prepared according to the manufacturer’s instructions. Expression
levels of IL-12, IL-10, IL-1a, IL-1b, IL-1Ra, IL-18, IL-6, interferon-g,
MIF, L32 ribosomal protein, and glyceraldehyde-3-phosphate
dehydrogenase mRNA were analyzed by RiboQuant RNase protec-
tion assay, using the mCK-2b multi-probe template set from BD
Biosciences (Heidelberg, Germany). Briefly, riboprobes were 32P-
labeled and hybridized overnight in solution with 10 mg total RNA.
The hybridized RNA was digested with RNases A and T1 and
the remaining RNase-protected probes were purified, resolved on
denaturing polyacrylamide gels, and imaged by autoradiography
according to the RiboQuant protocol. The protected bands
representing cytokine mRNA expression were quantified by phos-
phorimaging using a Cyclone Storage Phosphor System (PerkinElmer
Life Sciences, Zaventem, Belgium) and normalized for L32 mRNA
expression. Cytokines detectable in acetone and/or PMA-treated
skin were IL-1a, IL-1b, IL-1Ra, IL-18, IL-6, and MIF.
Measurement of circulating SAA and IL-6 levels
Blood was taken at the end of experiment by cardiac puncture.
Serum levels of SAA were determined using a direct ELISA, as
described previously (Sipe et al., 1989). The detection limit for this
test is 13 mg/ml. Serum levels of IL-6 were measured using a
commercial DuoSet ELISA Development System from R&D Systems
(Abington, UK). The detection limit for this test is 39 pg/ml.
Measurement of IL-1a and IL-1b protein levels in skin extracts
Small pieces of the skin were homogenized in ice-cold lysis (50 mM
Tris pH 7.4, 150 mM NaCl, 1 mM phenylmethanesulfonyl fluoride,
0.5% Triton X-100) and the lysates were cleared by centrifugation at
13,000 r.p.m., 41C for 15 minutes. Protein concentration in the
lysates was assessed using the Biorad DC protein assay kit (Bio-Rad
Laboratories, Hercules, CA). IL-1a and IL-1b concentrations were
determined using commercial DuoSet ELISA Development Systems
(R&D Systems, Abington, UK). Detection limit is 16 pg/ml for IL-1a
and IL-1b.
Immunohistochemistry for IL-1a
IL-1a expression was detected by immunohistochemistry on paraffin-
embedded sections. The sections were deparaffinized, rehydrated,
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and boiled for 10 minutes in citrate buffer (10 mM, pH 6) in a
microwave oven for heat-induced antigen retrieval. Endogenous
peroxidase activity was blocked with 0.6% H2O2 in methanol:H2O
(1:1) for 10 minutes. Sections were permeabilized in phosphate-
buffered saline containing 0.1% Triton X-100 for 15 minutes and
blocked with phosphate-buffered saline containing 3% BSA and
10% normal goat serum for 1 hour at RT. Sections were then stained
using a rabbit polyclonal anti-IL-1a antibody (sc-7929; Santa Cruz
Biotechnologies, Santa Cruz, CA; 1/100) in phosphate-buffered
saline containing 1.5% BSA and 5% normal goat serum overnight at
41C. After washing in phosphate-buffered saline, bound antibody
was visualized using a biotinylated goat anti-rabbit secondary
antibody (DakoCytomation AG, Baar, Switzerland; 1/250), the
avidin–biotin–peroxidase complex and 3,30-diaminobenzidine
(DakoCytomation) as a chromogen. Slides were counterstained
with hemalun. An incubation without the first antibody served as
a negative control.
Statistical analysis
Significance of differences was calculated by Student’s unpaired
t-test or analysis of variance (ANOVA) as appropriate. A difference
between experimental groups was considered significant when the
P-value was o0.05.
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